# Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

> **NCT04259255** · — · UNKNOWN · sponsor: **Tanabe Pharma America, Inc.** · enrollment: 300 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis
- ALS

## Interventions

- **DRUG:** Edaravone (Radicava®/Radicava ORS®)

## Key facts

- **NCT ID:** NCT04259255
- **Lead sponsor:** Tanabe Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-21
- **Primary completion:** 2024-03
- **Final completion:** 2024-03
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2023-08-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04259255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04259255, "Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04259255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*